The most recent trading session ended with Pacific Biosciences of California (PACB) standing at $1.81, reflecting a +0.56% shift from the previouse trading day's closing. The stock outperformed the S&P 500, which registered a daily gain of 0.54%. At the same time, the Dow added 0.72%, and the tech-heavy Nasdaq gained 0.65%.Prior to today's trading, shares of the maker of genetic analysis technology had gained 6.51% over the past month. This has outpaced the Medical sector's gain of 4.37% and the S&P 500's g ...

Pacific Biosciences of California, Inc. (PACB) or PacBio recently announced a collaboration with HiFi Solves Sub-Fertility Consortium, led by KK Women’s and Children’s Hospital in Singapore. The consortium will use PACB’s HiFi long-read sequencing to pioneer advancements in diagnosing and treating subfertility and recurrent pregnancy loss (RPL). The consortium includes experts from five leading centers across the Asia-Pacific region and leverages DNAstack’s federated data platform to ensure secure, global c ...

Pacific Biosciences of California, Inc. (PACB) has announced a collaboration with the University Hospital of Munster to use its Revio HiFi sequencing system in advancing research on male infertility and rare diseases.Munster is pioneering long-read whole genome sequencing in Germany, integrating it into research and diagnostics. This initiative will explore complex genetic issues, including the Y chromosome’s role in male infertility, and support Germany’s GenomeDE Modellvorhaben project. The results will a ...

SINGAPORE, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The HiFi Solves Sub-fertility Consortium, an innovative collaboration involving five leading centers across the Asia-Pacific region, announces work aimed at redefining the landscape of fertility research. Utilizing PacBio HiFi long-read sequencing, the consortium, led by KK Women's and Children's Hospital (KKH) in Singapore, is pioneering the use of PacBio HiFi long-read sequencing to enhance the diagnosis and treatment of subfertility and recurrent miscarriages ...

MENLO PARK, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced a collaboration with the University Hospital of Münster, to use long-read whole genome sequencing to significantly advance male infertility and rare disease research. By deploying PacBio’s Revio HiFi sequencing system, researchers at Münster will obtain highly accurate genomic data essential for addressing complex genetic issues associated w ...

Mongkol Onnuan Pacific Biosciences: Sustained Weakness in Genomic Sequencing Market Pacific Biosciences of California's (NASDAQ:PACB) stock is down 20% since my "sell" recommendation in June following its Q1 earnings report. I expressed concerns regarding Pacific's "high SG&A costs (relative to revenues), declining product revenues, and low gross margins" amidst a competitive genomic sequencing market. The company reported Q2 earnings on August 7. Unfortunately, the results continue to highlight the signifi ...

alanphillips/E+ via Getty Images The performance of Pacific Biosciences (NASDAQ:PACB) (“PacBio”) is all too familiar to readers who’ve followed this stock for a long time, as once again the stock is trading below $2 on fears that the company simply won’t be able to stay in the game long enough to benefit from future growth in long-read sequencing (as well as skepticism that long-read sequencing will grow enough to support a $1B+ revenue base). Down more than 80% since my last update, underperforming oth ...

Pacific Biosciences of California (PACB) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following y ...

财务业绩 - 收入下降24%至3600万美元，主要由于Revio系统销量下降[117] - 总收入下降13%至74.8百万美元[129] - 仪器收入下降33%至33.7百万美元[129] - 耗材收入增长24%至1700万美元，主要由于Revio耗材销量增加[117] - 耗材收入增长19%至33.0百万美元[129] - 服务及其他收入增长9%至426.7万美元[117] - 毛利率下降至23%，主要由于收入下降、重组费用和无形资产摊销增加[112] - 毛利率下降至23%[130] 经营情况 - Revio系统销量从去年同期45台下降至24台[117] - 经营亏损增加至1.758亿美元，主要由于收入下降、商誉减值9320万美元和运营费用增加[116] - 研发费用下降14%至81.9百万美元[131] - 销售及管理费用增加11%至89.6百万美元[132] - 计提9.32亿美元商誉减值[133] - 收购相关无形资产摊销费用增加至9.7百万美元[134] - 应收或有对价公允价值变动收益0.07百万美元[135] 现金流与流动性 - 现金及短期投资余额为5.098亿美元，较2023年末下降19%[112] - 公司现金、现金等价物和投资总额为5.098亿美元，较2023年12月31日的6.314亿美元有所下降[32] - 公司主要通过发行债务或股权证券以及经营活动产生的现金流来维持流动性[32] - 公司2024年上半年经营活动使用现金1.299亿美元,主要由于计提了9.32亿美元的商誉减值[43] - 公司2024年上半年投资活动提供现金4,270.1万美元,主要由于投资到期赎回[45] - 公司2024年上半年筹资活动提供现金640.1万美元,主要由于发行普通股[46] - 公司与Apton收购相关存在或有对价安排,最高可达2,500万美元[40] - 公司投资组合中的固定收益证券公允价值每上升或下降100个基点将影响约260万美元[53] 未来展望 - 预计2024年剩余时间研发和销售费用将继续下降，以配合公司的精简计划[112] - 公司批准并开始实施若干效率和开支减少措施,预计到2024年底将减少年度经营开支[32]

Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, delivered an adjusted loss per share of 20 cents in second-quarter 2024, narrower than the year-ago quarter’s loss of 26 cents per share. The adjusted loss per share beat the Zacks Consensus Estimate by 16.7%.The company’s GAAP loss per share was 64 cents in the quarter, wider than the year-ago period’s loss of 28 cents.Revenues in DetailPacBio registered revenues of $36 million in the second quarter, down 24.3% year over year. The ...